50 million LymPro revenue x 16 would be 800 million. And, based on 800 million outstanding shares, that would put us at $1.00 following revenue guidance. (Plus, whatever value an analyst would place on MANF & Elto) I can see an analyst giving us a Price Target above $1.00 by September.
The question is whether or not our pps will respond to that target by November when we up list? If Gerald just throws out some simple estimates and doesn't really reveal how he came up with his 2015 revenue guidance, the market may not take it seriously enough to push us over $1.00.
I think his LymPro Guidance is very critical to his entire plan, including the final deal he strikes with our LymPro partner. He needs to put forth a strong revenue model for LymPro to get the partner to put up 100 million in cash up front!!
As I see it we have three huge LymPro catalysts in August: 1) Releasing the latest LymPro data at the Conference, 2) LymPro Revenue Guidance, & 3) Announcing a LymPro Partner.
News 
Market Data 
Discover 
